Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects

Eitemau Tebyg

• Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
  gan: Gu, Namyi, et al.
  Cyhoeddwyd: (2014)
• Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
  gan: Rhee, Su-jin, et al.
  Cyhoeddwyd: (2016)
• Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
  gan: Yoo, Hyounggyoon, et al.
  Cyhoeddwyd: (2020)
• Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
  gan: Hwang, Inyoung, et al.
  Cyhoeddwyd: (2020)
• Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
  gan: Gu N, et al.
  Cyhoeddwyd: (2014-10-01)